Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-02-10

Clinical Trial Update: Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children. [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the impact of the 13-valent pneumococcal conjugate vaccine in Alaskan Native children; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease, 13-valent Pneumococcal Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2012-02-10